FDA approves Bristol-Myers' immunotherapy for skin cancer

December 22, 2014 8:35 PM

13 0

(Reuters) - The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date.

Opdivo, or nivolumab, belongs to a promising new class of drugs designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1).

Read more

To category page